Kristi B.
- Country
- France
- Department
- Département d'innovation thérapeutique et essais précoces (DITEP)
Research Overview
Data & Insights
Has run more than one trial at 0 of 4 partner sites.
Specializations
Myeloid Hematologic Malignancies
Focused investigation of Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Lymphoblastic Leukemia in relapsed or refractory settings.
- Targeted therapies for IDH1/2‑mutated AML
- Novel agents for high‑risk MDS
- Combination regimens for CMML
- Immunomodulatory strategies for adult ALL
Research emphasizes molecular profiling and resistance mechanisms to improve outcomes in adult patients.
MTAP‑Deleted Solid Tumors
Clinical evaluation of therapies directed at cancers harboring MTAP‑deleted alterations, including advanced Non‑Small Cell Lung Cancer, Mesothelioma, Sarcoma, Pancreatic Ductal Adenocarcinoma and Glioblastoma.
- Selective inhibitors for MTAP‑deficient NSCLC
- Targeted approaches in MTAP‑deleted mesothelioma
- Combination strategies for MTAP‑null sarcoma
- Novel agents for MTAP‑deleted pancreatic cancer
- Therapeutics for MTAP‑deficient glioblastoma
Efforts aim to exploit synthetic lethality associated with MTAP loss.
HER2‑Driven Breast and Gastro‑Gastric Cancers
Investigation of targeted and antibody‑drug conjugate therapies in HER2‑positive and HER2‑low breast cancer, as well as HER2‑expressing Gastric cancer and Gastro‑Esophageal Junction adenocarcinoma.
- ADCs for HER2‑positive metastatic breast cancer
- Therapies for HER2‑low breast tumors
- HER2‑targeted regimens in advanced gastric carcinoma
- Combination strategies with HER2‑directed agents
Research prioritizes overcoming resistance to existing HER2‑targeted therapies.
Pediatric and Rare Solid Tumor Oncology
Clinical programs addressing rare and pediatric malignancies such as Neuroendocrine tumors, High‑grade glioma, Rhabdomyosarcoma, Ewing sarcoma and other uncommon sarcomas.
- Targeted agents for pediatric high‑grade glioma
- Novel therapies for neuroendocrine tumors of the lung and gut
- Precision medicine approaches for rhabdomyosarcoma
- Combination regimens for Ewing sarcoma
- Immunotherapy trials in rare sarcoma subtypes
Emphasis is placed on molecularly guided treatment for underserved tumor types.
Immunotherapy and Checkpoint Modulation
Development of immune‑based strategies involving PD‑1, PD‑L1 blockade, CD137 agonists and other checkpoint modulators across multiple tumor indications.
- PD‑1/PD‑L1 inhibitors in metastatic melanoma
- Checkpoint blockade combined with targeted agents in NSCLC
- CD137 agonist trials in solid tumors
- Immune‑oncology combinations for renal cell carcinoma
- Biomarker‑driven immunotherapy for MSI‑high and TMB‑high cancers
Research integrates predictive biomarkers to optimize patient selection for immune‑based therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.